Antibody-based Vectored Immunoprophylaxis Provides High-titer Plasmodium Falciparum Circumsporozoites Antibodies
Generated by an autonomous AI research agent — Anthropic Claude Opus 4.7 or OpenAI GPT-5.5, max reasoning effort. Sources cited inline. Full disclosure at /methodology/jhtv-deep-dive.
Indication
malaria (Plasmodium falciparum)
Modality
Monoclonal Antibody
Mechanism
vectored immunoprophylaxis / antibody-based anti-malarial
Target
Plasmodium falciparum circumsporozoite protein (CSP)
rNPV Envelope
Low
-$69.2M
costs +25% · peak −25%
Base
-$48.4M
cumulative PoS 8.6%
High
-$27.5M
costs −25% · peak +25%
Malaria immunoprophylaxis is costed as a biologic/vaccine program with large field-trial logistics but non-premium pricing. PoS is kept moderate because public-health implementation and durable efficacy matter as much as antibody titers.
Composite score breakdown
Locked rubric — 40/30/30 weights
Clinical relevance · 40%
0.80
Modality fit · 30%
0.51
Whitespace · 30%
0.50
Composite 0.624 — composite-score rank #20 of 50 top-tier inventions in the jhtv-portfolio@2026-Q2 cohort. The page header uses rNPV rank (#45) to match the index ordering.
Comparators
Real programs anchoring the engine inputs
Mosquirix (GSK/PATH) — RTS,S/AS01 malaria vaccine
First recommended malaria vaccine and best public-procurement revenue analogue.
Criteria 2: same malaria prevention indication; grant/Gavi procurement rather than standard commercial launch.
R21/Matrix-M (Oxford/Serum Institute/Novavax) — malaria vaccine
Second WHO-recommended malaria vaccine showing current development and procurement pathway.
Criteria 2 and 3: same malaria prevention indication and WHO/Gavi implementation pathway.
PfSPZ Vaccine (Sanaria) — whole-sporozoite malaria vaccine
Advanced malaria immunoprophylaxis program with challenge-model and endemic-region data.
Criteria 2 and 4: same malaria prevention market and biologic immunoprophylaxis modality.
Stage profile
Asset-specific cost, duration, and PoS by stage
| Stage | Cost | Duration | PoS | Citations |
|---|---|---|---|---|
| Preclinical | $15.0M | 24 mo | 45.0% | [0] [2] [4] |
| Phase I | $45.0M | 18 mo | 65.0% | [2] [4] [5] |
| Phase II | $100.0M | 30 mo | 50.0% | [0] [1] [5] |
| Phase III | $180.0M | 36 mo | 65.0% | [0] [1] [5] |
| NDA/BLA Review | $12.0M | 12 mo | 90.0% | [0] [1] [5] |
Multiplier handling: No multipliers eligible for this asset under the locked methodology. See methodology for the rule.
Peak revenue and discount rate
$75.0M peak · WACC 8.0%
Peak revenue. The value model is public procurement rather than VC-style premium pricing. A $75M annual peak sits above the locked Mosquirix proxy because vectored antibody protection could differentiate clinically, but it remains grant/Gavi-funded rather than a standard commercial franchise.
WACC. Grant and procurement funding lowers financial discounting but also caps commercial upside.
Sensitivity (tornado)
Top drivers of rNPV variance
Drivers ranked by absolute rNPV swing. The vertical tick inside each bar marks the base rNPV (-$48.4M); each bar spans the rNPV range produced by flexing one input between its low and high values. Gold = the input pushes rNPV up when increased; red = the input pushes rNPV down when increased.
Monte Carlo distribution
1,000 trials · rpNPV mode
This is a bimodal distribution by construction, not a Gaussian. Most paths terminate in clinical failure (red cluster — accumulated cost only); a minority succeed and capture full peak revenue (green tail). Bar heights are square-root-scaled so the success tail stays visible alongside the much taller failure cluster; exact counts are preserved in the percentiles below. Gold line = median (P50). Navy dashed = base rNPV (mean) — the probability-weighted expected value, which can sit above the median when the upper tail is strong enough to outweigh the failure cluster (and close to the median when it isn’t).
P5
-$176.6M
P25
-$59.6M
P50 (median)
-$18.1M
P75
-$9.5M
P95
-$3.7M
Prob ≥ 0
4.0%
Comparable launch curves
Revenue trajectories of named comparators
Mosquirix (GSK/PATH) — RTS,S/AS01 malaria vaccine
Launched 2021 · peak $47.5M (estimated)
Evidence register
6 per-assumption citations
| Assumption | Source | Date | Confidence |
|---|---|---|---|
Mosquirix allocation/procurement benchmark comparators[0] | WHO/Gavi/UNICEF allocate 18 million doses of first malaria vaccine for 2023-2025 regulatory | 2023-07-05 | high |
RTS,S implementation mortality signal stage_profile.phase_3.pos | Gavi: RTS,S vaccine pilot mortality reduction fuels hope for malaria control news | 2023-11-01 | medium |
R21 WHO recommendation comparators[1] | WHO recommends R21/Matrix-M vaccine for malaria prevention regulatory | 2023-10-02 | high |
R21 prequalification stage_profile.nda_bla.duration_months | WHO prequalifies a second malaria vaccine regulatory | 2023-12-21 | high |
PfSPZ advanced malaria vaccine comparator comparators[2] | Sanaria press release: first PfSPZ malaria vaccine trial in Indonesia news | 2024-08-01 | medium |
Vaccine/public-health PoS sanity stage_profile.phase_2.pos | BIO/QLS/Informa Clinical Development Success Rates 2011-2020 peer_review | 2021-02-17 | medium |
Thesis
Why this asset earns its rank
The malaria vectored-immunoprophylaxis asset is clinically relevant because it targets a disease with enormous mortality but limited commercial pricing power. The biology is antibody-based protection against Plasmodium falciparum CSP, which is adjacent to vaccine-mediated circumsporozoite immunity rather than a premium therapeutic launch.
Mosquirix, R21/Matrix-M, and PfSPZ define the correct frame: global-health procurement, field efficacy, manufacturing capacity, and funder adoption matter more than U.S. orphan economics. The engine result is -$69.2M to -$27.5M, with a base rNPV of -$48.4M and cumulative PoS of 8.6%; the rNPV is not the decision criterion here, which is why the asset is classified as grant_non_commercial despite clear public-health value.
The verdict is a top-10 public-health asset, not a conventional VC asset. It earns its ranking on clinical relevance and whitespace, while the funding path should be Gates, Gavi, NIH, or product-development partnership rather than standalone biotech equity.
Key risks
Asset-specific, not generic biotech risks
- High antibody titers may not translate into durable protection in endemic field settings.
- Manufacturing and cold-chain requirements must fit low-margin global-health procurement.
- R21/Matrix-M and RTS,S already occupy the vaccine implementation pathway.
- Funding depends on donor and Gavi priorities rather than commercial payer demand.